Adma Biologics reported $26.14M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Adamis Pharmaceuticals ADMP:US 689.18K 774.4K
Adma Biologics ADMA:US $ 26.14M 0.7M
Agile Therapeutics AGRX:US 2.23M 704K
Alnylam Pharmaceuticals ALNY:US $ 40.81M 5.18M
Biocryst Pharmaceuticals BCRX:US $ 0.25M 0.01M
Dynavax Technologies DVAX:US $ 83.37M 43.41M
Novavax NVAX:US 271.08M 255.87M
Takeda 4502:JP Y 292882M 15498M